Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a first generation antihistamine drug (Ethanolamine) with a strong sedative effect.
A high protein-binding capacity makes difficult an excretion into breast milk in significant amounts in accordance with old studies that had confirmed it.
The absorption from ingested mother's milk to the infant's plasma is hampered by a low oral bioavailability.
For both, the mother and the infant is safer the use of antihistamine medication with higher safety levels without sedative effect, especially when the child is a premature or younger than 1 month old.
Neither a decrease of milk production nor alteration of Prolactin release have been shown with the use of this drug.
When used while breastfeeding do it with the lower dose as possible and avoid a long-term use.
Check up for feeding difficulty and somnolence in the infant.
Bed-sharing with the infant is not recommended for parents who are on this medication.